Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)

Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Uttam K., Engelhardt, Brian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atlantis Press 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432328/
https://www.ncbi.nlm.nih.gov/pubmed/34595450
http://dx.doi.org/10.2991/chi.d.200506.002
_version_ 1783751136998588416
author Rao, Uttam K.
Engelhardt, Brian G.
author_facet Rao, Uttam K.
Engelhardt, Brian G.
author_sort Rao, Uttam K.
collection PubMed
description Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is characterized by immune dysregulation that can negatively impact transplant outcomes. This review will discuss the biology of IL-33/ST2 in acute GVHD and PTDM development, and how this cytokine axis could be leveraged for predicting and treating immuno-metabolic complications after transplant.
format Online
Article
Text
id pubmed-8432328
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Atlantis Press
record_format MEDLINE/PubMed
spelling pubmed-84323282021-09-29 Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2) Rao, Uttam K. Engelhardt, Brian G. Clin Hematol Int Review Patients undergoing allogeneic hematopoietic cell transplantation (HCT) are at risk for numerous acute and long-term complications from this procedure. Post-transplant diabetes mellitus (PTDM) is a common but under-recognized problem. Similar to graft-versus-host disease (GVHD), new-onset diabetes is characterized by immune dysregulation that can negatively impact transplant outcomes. This review will discuss the biology of IL-33/ST2 in acute GVHD and PTDM development, and how this cytokine axis could be leveraged for predicting and treating immuno-metabolic complications after transplant. Atlantis Press 2020-05-21 /pmc/articles/PMC8432328/ /pubmed/34595450 http://dx.doi.org/10.2991/chi.d.200506.002 Text en © 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ).
spellingShingle Review
Rao, Uttam K.
Engelhardt, Brian G.
Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
title Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
title_full Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
title_fullStr Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
title_full_unstemmed Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
title_short Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2)
title_sort predicting immuno-metabolic complications after allogeneic hematopoietic cell transplant with the cytokine interleukin-33 (il-33) and its receptor serum-stimulation 2 (st2)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432328/
https://www.ncbi.nlm.nih.gov/pubmed/34595450
http://dx.doi.org/10.2991/chi.d.200506.002
work_keys_str_mv AT raouttamk predictingimmunometaboliccomplicationsafterallogeneichematopoieticcelltransplantwiththecytokineinterleukin33il33anditsreceptorserumstimulation2st2
AT engelhardtbriang predictingimmunometaboliccomplicationsafterallogeneichematopoieticcelltransplantwiththecytokineinterleukin33il33anditsreceptorserumstimulation2st2

Ejemplares similares